{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:20:27Z","timestamp":1792592427641,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03778-2","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T09:33:39Z","timestamp":1744104819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["High sensitivity C-reactive protein implicates heterogeneous metabolic phenotypes and severity in metabolic dysfunction associated-steatotic liver disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Hao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youpeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihui","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"5","key":"3778_CR1","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"issue":"4","key":"3778_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041158","volume":"13","author":"T Miwa","year":"2024","unstructured":"Miwa T, Tajirika S, Imamura N, et al. Prevalence of steatotic liver disease based on a new nomenclature in the Japanese population: a health checkup-based cross-sectional study. J Clin Med. 2024;13(4): 1158.","journal-title":"J Clin Med"},{"issue":"1","key":"3778_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"3778_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/liv.14847","volume":"41","author":"D Maya-Miles","year":"2021","unstructured":"Maya-Miles D, Ampuero J, Gallego-Dur\u00e1n R, et al. Management of NAFLD patients with advanced fibrosis. Liver Int. 2021;41(Suppl 1):95\u2013104.","journal-title":"Liver Int"},{"key":"3778_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.1012887","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang J, Wang M, Wu Y, et al. Serum high-sensitive C-reactive protein is a simple indicator for all-cause among individuals with MAFLD. Front Physiol. 2022;13: 1012887.","journal-title":"Front Physiol"},{"issue":"3","key":"3778_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032997","volume":"13","author":"XD Zhou","year":"2024","unstructured":"Zhou XD, Chen QF, Targher G, et al. High-sensitivity C-reactive protein is associated with heart failure hospitalization in patients with metabolic dysfunction-associated fatty liver disease and normal left ventricular ejection fraction undergoing coronary angiography. J Am Heart Assoc. 2024;13(3): e032997.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"3778_CR7","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s00125-004-1472-x","volume":"47","author":"DE Laaksonen","year":"2004","unstructured":"Laaksonen DE, Niskanen L, Nyyss\u00f6nen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia. 2004;47(8):1403\u201310.","journal-title":"Diabetologia"},{"issue":"6","key":"3778_CR8","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1002\/bab.2310","volume":"69","author":"H Ma","year":"2022","unstructured":"Ma H, Mao Q, Zhu Y, et al. Time-resolved fluorescence immunoassay (TRFIA) for the simultaneous detection of hs-CRP and lipoprotein(a) in serum. Biotechnol Appl Biochem. 2022;69(6):2617\u201323.","journal-title":"Biotechnol Appl Biochem"},{"issue":"1","key":"3778_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hep.28776","volume":"65","author":"V Ajmera","year":"2017","unstructured":"Ajmera V, Perito ER, Bass NM, et al. NASH clinical research network. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology. 2017;65(1):65\u201377.","journal-title":"Hepatology"},{"issue":"7","key":"3778_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/hep4.1068","volume":"1","author":"ER Perito","year":"2017","unstructured":"Perito ER, Ajmera V, Bass NM, et al. Association between cytokines and liver histology in children with nonalcoholic fatty liver disease. Hepatol Commun. 2017;1(7):609\u201322.","journal-title":"Hepatol Commun"},{"issue":"1","key":"3778_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12933-022-01701-7","volume":"21","author":"D Wu","year":"2022","unstructured":"Wu D, Lan Y, Xu Y, et al. Association of cumulative monocyte to high-density lipoprotein ratio with the risk of type 2 diabetes: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):268.","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"3778_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/0003319719845186","volume":"70","author":"A Kurtul","year":"2019","unstructured":"Kurtul A, Ornek E. Platelet to lymphocyte ratio in cardiovascular diseases: a systematic review. Angiology. 2019;70(9):802\u201318.","journal-title":"Angiology"},{"issue":"6","key":"3778_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00403-020-02129-3","volume":"313","author":"A Demirba\u015f","year":"2021","unstructured":"Demirba\u015f A, Elmas \u00d6F, Atasoy M, et al. Can monocyte to HDL cholesterol ratio and monocyte to lymphocyte ratio be markers for inflammation and oxidative stress in patients with vitiligo? A preliminary study. Arch Dermatol Res. 2021;313(6):491\u20138.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"3778_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12944-021-01462-4","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu Z, Fan Q, Wu S, et al. Compared with the monocyte to high-density lipoprotein ratio (MHR) and the neutrophil to lymphocyte ratio (NLR), the neutrophil to high-density lipoprotein ratio (NHR) is more valuable for assessing the inflammatory process in Parkinson\u2019s disease. Lipids Health Dis. 2021;20(1):35.","journal-title":"Lipids Health Dis"},{"key":"3778_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.762242","volume":"12","author":"J Jia","year":"2021","unstructured":"Jia J, Liu R, Wei W, et al. Monocyte to high-density lipoprotein cholesterol ratio at the nexus of type 2 diabetes mellitus patients with metabolic-associated fatty liver disease. Front Physiol. 2021;12: 762242.","journal-title":"Front Physiol"},{"issue":"26","key":"3778_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011138","volume":"97","author":"JS Lee","year":"2018","unstructured":"Lee JS, Kim NY, Na SH, et al. Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. Medicine (Baltimore). 2018;97(26): e11138.","journal-title":"Medicine (Baltimore)"},{"key":"3778_CR17","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2147\/DMSO.S238990","volume":"13","author":"T Chen","year":"2020","unstructured":"Chen T, Chen H, Xiao H, et al. Comparison of the value of neutrophil to high-density lipoprotein cholesterol ratio and lymphocyte to high-density lipoprotein cholesterol ratio for predicting metabolic syndrome among a population in the southern coast of China. Diabetes Metab Syndr Obes. 2020;13:597\u2013605.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"6","key":"3778_CR18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0736-4679(99)00135-3","volume":"17","author":"B Clyne","year":"1999","unstructured":"Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med. 1999;17(6):1019\u201325.","journal-title":"J Emerg Med"},{"issue":"1","key":"3778_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.amjcard.2010.02.017","volume":"106","author":"GC Brooks","year":"2010","unstructured":"Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to abdominal adiposity. Am J Cardiol. 2010;106(1):56\u201361.","journal-title":"Am J Cardiol"},{"issue":"2","key":"3778_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/hep.30429","volume":"70","author":"RS Khan","year":"2019","unstructured":"Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70(2):711\u201324.","journal-title":"Hepatology"},{"key":"3778_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00040","volume":"10","author":"F Bian","year":"2019","unstructured":"Bian F, Yang XY, Xu G, Zheng T, Jin S. Crp-induced NLRP3 inflammasome activation increases LDL transcytosis across endothelial cells. Front Pharmacol. 2019;10: 40.","journal-title":"Front Pharmacol"},{"issue":"10","key":"3778_CR22","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3390\/biomedicines11102711","volume":"11","author":"Z Ding","year":"2023","unstructured":"Ding Z, Wei Y, Peng J, Wang S, Chen G, Sun J. The potential role of C-reactive protein in metabolic-dysfunction-associated fatty liver disease and aging. Biomedicines. 2023;11(10):2711.","journal-title":"Biomedicines"},{"issue":"2","key":"3778_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2009.03.019","volume":"51","author":"CK Argo","year":"2009","unstructured":"Argo CK, Northup PG, Al-Osaimi AM, et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51(2):371\u20139.","journal-title":"J Hepatol"},{"key":"3778_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.898931","volume":"9","author":"L Wang","year":"2022","unstructured":"Wang L, Dong J, Xu M, et al. Association between monocyte to high-density lipoprotein cholesterol ratio and risk of non-alcoholic fatty liver disease: a cross-sectional study. Front Med (Lausanne). 2022;9: 898931.","journal-title":"Front Med (Lausanne)"},{"key":"3778_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.981196","volume":"13","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Xia J, He H, et al. Diagnostic performance of novel inflammatory biomarkers based on ratios of laboratory indicators for nonalcoholic fatty liver disease. Front Endocrinol (Lausanne). 2022;13: 981196.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"3778_CR26","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.2337\/dc09-0176","volume":"32","author":"E Lapice","year":"2009","unstructured":"Lapice E, Maione S, Patti L, et al. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care. 2009;32(9):1734\u20136.","journal-title":"Diabetes Care"},{"key":"3778_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.848937","volume":"13","author":"C Zhu","year":"2022","unstructured":"Zhu C, Huang D, Ma H, et al. High-sensitive CRP correlates with the severity of liver steatosis and fibrosis in obese patients with metabolic dysfunction associated fatty liver disease. Front Endocrinol (Lausanne). 2022;13: 848937.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"3778_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2022.09.027","volume":"164","author":"H Li","year":"2023","unstructured":"Li H, Zheng J, Xu Q, et al. Hepatocyte adenosine kinase promotes excessive fat deposition and liver inflammation. Gastroenterology. 2023;164(1):134\u201346.","journal-title":"Gastroenterology"},{"issue":"19","key":"3778_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph191912221","volume":"19","author":"AL Ordo\u00f1ez-V\u00e1zquez","year":"2022","unstructured":"Ordo\u00f1ez-V\u00e1zquez AL, Ju\u00e1rez-Hern\u00e1ndez E, Zuarth-V\u00e1zquez JM, et al. Impact on prevalence of the application of NAFLD\/MAFLD criteria in overweight and normal weight patients. Int J Environ Res Public Health. 2022;19(19): 12221.","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"3778_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00535-007-2060-x","volume":"42","author":"M Yoneda","year":"2007","unstructured":"Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007;42(7):573\u201382.","journal-title":"J Gastroenterol"},{"issue":"1","key":"3778_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41043-023-00372-8","volume":"42","author":"T Jamialahmadi","year":"2023","unstructured":"Jamialahmadi T, Bo S, Abbasifard M, et al. Association of C-reactive protein with histological, elastographic, and sonographic indices of non-alcoholic fatty liver disease in individuals with severe obesity. J Health Popul Nutr. 2023;42(1):30.","journal-title":"J Health Popul Nutr"},{"issue":"1","key":"3778_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3350\/cmh.2022.0237","volume":"29","author":"KC Lee","year":"2023","unstructured":"Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2023;29(1):77\u201398.","journal-title":"Clin Mol Hepatol"},{"key":"3778_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.691556","volume":"12","author":"T Wu","year":"2021","unstructured":"Wu T, Ye J, Shao C, et al. Varied relationship of lipid and lipoprotein profiles to liver fat content in phenotypes of metabolic associated fatty liver disease. Front Endocrinol (Lausanne). 2021;12: 691556.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"3778_CR34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157906","volume":"7","author":"KF Petersen","year":"2022","unstructured":"Petersen KF, Dufour S, Li F, et al. Ethnic and sex differences in hepatic lipid content and related cardiometabolic parameters in lean individuals. JCI Insight. 2022;7(7): e157906.","journal-title":"JCI Insight"},{"issue":"1","key":"3778_CR35","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12967-023-04367-1","volume":"21","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Wang S, Wu J, Wang Y. Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy. J Transl Med. 2023;21(1):510.","journal-title":"J Transl Med"},{"issue":"8","key":"3778_CR36","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/hepr.13906","volume":"53","author":"T Miwa","year":"2023","unstructured":"Miwa T, Francisque C, Tajirika S, et al. Impact of body fat accumulation on metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults. Hepatol Res. 2023;53(8):691\u2013700.","journal-title":"Hepatol Res"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03778-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03778-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03778-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:22:31Z","timestamp":1744204951000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03778-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3778"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03778-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"9 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (Approval number: [2020] No. 187) and registered with the Chinese Clinical Trial Registry (ChiCTR-ChiCTR2000034197). The study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}